An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

Alicia K. Morgans1*, Thomas Hutson2, Alice Kai Dan Guan3, David Garcia3*, Anna Zhou3, Edward Drea4 and Nicholas J. Vogelzang5

Abstract

Background: Cabazitaxel significantly improves clinical outcomes compared with a second androgen receptor-targeted agent (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and an ARTA (abiraterone or enzalutamide), as demonstrated in the CARD trial (NCT02485691). We aimed to estimate healthcare costs avoided with the use of cabazitaxel as a third-line (3L) treatment versus a second ARTA from a US payer perspective.

Methods: Model inputs were based on the CARD trial, published sources, and estimates of typical clinical care patterns by genitourinary oncologists (n = 3). Assessed time points were 6, 12, 18, and 24 months. Outcomes included progression-free survival (PFS), radiographic PFS (rPFS), and overall survival (OS); hospitalization and intensive care unit (ICU) days; and costs (reported in 2020 US dollar [USD] and converted into Euro) to manage symptomatic skeletal events (SSEs), adverse events (AEs), and end-of-life care.

Results: At 18 months, in a cohort of 100 patients, the use of cabazitaxel was estimated to result in 9 more patients achieving rPFS, 2 more patients achieving PFS, and 17 more survivors versus a second ARTA. The costs of SSEs, AEs, and end-of-life care were $498,909 (€424,073), $276,198 (€234,768), and $808,785 (€687,468), respectively, for cabazitaxel and $627,569 (€533,434), $251,124 (€213,455), and $1,028,294 (€874,050), respectively, for a second ARTA. Cabazitaxel was estimated to be associated with a 21% reduction in both SSE management and end-of-life care costs.
Background
Prostate cancer is the second leading cause of cancer-related mortality among men in the United States (US) [1]. In 2020, 191,930 new cases of prostate cancer were diagnosed in the US; about 10 to 20% of these cases are likely to develop into castration-resistant prostate cancer (CRPC) within 5 years of diagnosis [1]. Approximately 41% of patients with CRPC are metastatic at diagnosis [2]. Several therapies, including taxanes (e.g., cabazitaxel and docetaxel), androgen receptor-targeted agent (ARTA or androgen-signaling-targeted inhibitor [ASTI]; e.g., enzalutamide and abiraterone), a radiopharmaceutical agent (e.g., radium-223 and Lutetium-177), and an immunotherapy agent (e.g., sipuleucel-T), have improved survival for patients with metastatic CRPC (mCRPC) [3–9]. Docetaxel is the recommended first-line chemotherapy in patients with mCRPC [10]. In addition to docetaxel, ARTAs are commonly administered in the earlier stages of mCRPC [11].

After receiving docetaxel, patients who progress while receiving an ARTA may have a marginal response when switched to an alternative ARTA [12–17]. In contrast, studies have suggested that cabazitaxel retains a high level of anti-tumor activity in patients who have had disease progression while receiving docetaxel or ARTAs [3, 18]. In the CARD trial, cabazitaxel demonstrated a significant improvement in clinical outcomes including radiographic progression-free survival (rPFS, $p < 0.001$), PFS ($p < 0.001$), and overall survival (OS, $p = 0.008$) compared with a second ARTA [19]. Despite the favourable outcomes from the CARD trial, an optimal cost-effective third-line (3L) treatment for managing patients with mCRPC previously treated with docetaxel and an ARTA is currently unclear. Additionally, even though the current treatments have improved the median OS in patients with mCRPC [20], they are associated with higher healthcare resource utilization (HCRU), including for the management of symptomatic skeletal events (SSEs) and adverse events (AEs) [21]. McDougall et al. (2016) studied the economic impact of SSEs among Medicare-enrolled men with metastatic prostate cancer and determined that the attributable cost of ≥1 SSE management was $21,191 (US dollar [USD] 2016) [22]. A recent systematic review of cost-effectiveness and cost analyses reported that the annual direct healthcare cost of patients with mCRPC ranged between $26,707 and $67,957 (USD 2015) [23].

In countries like the US, the economic aspect has a greater influence on the clinician’s therapeutic choice than in other healthcare contexts [24]. Healthcare decision makers face a significant challenge to optimize the treatment landscape in terms of cost and effectiveness in patients with mCRPC previously treated with docetaxel who had progressed within 12 months while receiving an ARTA. To address this unmet need, based on the results of the CARD study, we developed an economic model to quantify the clinical outcomes, including rPFS, PFS, OS, hospitalization days, and intensive care unit (ICU) days, and to determine potential HCRU and associated costs avoided, from the United States payers’ perspective, in a hypothetical cohort of patients with mCRPC receiving cabazitaxel as a 3L treatment compared with a same size cohort receiving a second ARTA.

Methods
Analysis overview
An economic model was developed in Microsoft Excel to compare cabazitaxel as a 3L treatment with a second ARTA (abiraterone or enzalutamide) in patients with mCRPC from the US payers’ and population healthcare decision makers’ perspective. Efficacy and safety inputs were based on results from the CARD trial [19]. Inputs from three genitourinary oncologists (Alicia Morgans, Thomas Hutson, and Nicholas J. Vogelzang) were used to validate the assumptions and to inform clinical parameters, such as routine treatment of AEs, expected rates of hospitalization, and length of stay (LOS) for Grade 3/4 AEs and SSEs, which were not available in the published literature.

Given the short life expectancy for the target population (median OS of 11.0–13.6 months) [19], a time horizon of 18 months was used for the reference case analysis, and scenario analyses were conducted for time horizons

Conclusion: The use of cabazitaxel as a 3L treatment after docetaxel and an ARTA in patients with mCRPC is estimated to result in clinical benefits (longer rPFS, PFS, and OS) and lower healthcare resource utilization (fewer hospitalizations and ICU days), compared with a second ARTA.

Keywords: Cabazitaxel, Androgen receptor-targeted agent, Economic impact, Metastatic castration-resistant prostate cancer, Third-line treatment, Symptomatic skeletal events, End-of-life care
of 6, 12, and 24 months. The clinical outcomes assessed at the various time points (6, 12, 18, and 24 months) included rPFS, PFS, OS, and hospitalization days. The economic analysis included the costs associated with the management of SSEs, AEs, and end-of-life care. Costs specifically associated with inpatient stays were also estimated. All costs were adjusted to 2020 US dollars (USD, translated in Euro (€) to suit local readers, 1 US dollar equals 0.85 Euro per exchange rate as of August 30, 2021). Only direct costs were considered as the analysis was conducted from the US payers’ and population healthcare decision makers’ perspective.

**Clinical inputs**

This analysis estimated the proportion of patients achieving rPFS, PFS, and OS at 6, 12, 18, and 24 months using the Kaplan–Meier (KM) curves of respective events from the CARD trial (Supplementary Appendix 1). The incidence of SSEs (i.e., pathological fracture, radiation to bone, spinal cord compression, surgery to bone) was calculated as the overall monthly rate of SSEs multiplied by the total months of OS at 6, 12, 18, and 24 months for each treatment. The distribution of type of SSE was obtained from the CARD trial [25]. The overall monthly rates of SSEs were estimated based on the treatment-specific probabilities of SSEs and mean follow-up time reported from the CARD trial and the formula to convert probabilities to rates described by Fleurence and Hollenbeak (2007) [26] (Supplementary Appendix 2). To estimate the total months of OS at various time points, the OS KM curve was digitized (using Digitizelt software, version 2.5.3), and the median time of survival for patients with events during the intervals of interests (i.e., 0–6, 6–12, 12–18, and 18–24 months) was estimated. Then, the total time of survival at each time point was calculated. Supplementary Appendix 3 presents the estimates of total months of OS and number of SSEs for a cohort of 100 patients at each time point. This analysis considered all treatment-related Grade 3/4 AEs based on the National Cancer Institute (NCI)

| Event                                      | Cost      | Source of cost |
|--------------------------------------------|-----------|----------------|
| Symptomatic skeletal events                 |           |                |
| Radiation to bone                          | $6460 (€5491) | Carter et al. (2013) [30] |
| Pathological fracture                      | $31,387 (€26,679) | Carter et al. (2013) [30] |
| Spinal cord compression                     | $46,382 (€39,425) | Carter et al. (2013) [30] |
| Grade 3/4 adverse events                   |           |                |
| Asthenia or fatigue                         | $27 (€23) | Sorensen et al. (2013) [32] |
| Diarrhea                                    | $8268 (€7028) | Bui et al. (2016) [29] |
| Infection                                   | $9689 (€8236) | Bui et al. (2016) [29] |
| Musculoskeletal pain or discomfort          | $19 (€16) | Sorensen et al. (2013) [32] |
| Peripheral neuropathy                       | $748 (€636) | Costing methodology: Bilir et al. (2016) [28] |
| Renal disorder                              | $11,713 (€9956) | Bui et al. (2016) [29] |
| Cardiac disorder                            | $13,126 (€11,157) | Bui et al. (2016) [29] |
| Febrile neutropenia                         | $18,739 (€15,928) | Bui et al. (2016) [29] |
| Anemia                                      | $5063 (€4304) | Sorensen et al. (2013) [32] |
| Leukopenia                                  | $191 (€162) | Roy et al. (2015) [31] |
| Neutropenia                                 | $191 (€162) | Roy et al. (2015) [31] |
| Thrombocytopenia                            | $1266 (€1076) | Sorensen et al. (2013) [32] |
| Hyponatremia                                | $1354 (€1151) | Cost of outpatient management: Roy et al. (2015) [31] |

**Table 1** Published US costs of management of symptomatic skeletal events and Grade 3/4 adverse events

Abbreviations: CPT Current Procedural Terminology; LOS length of stay, US United States, USD US dollar

a Reported costs were inflated to 2020 USD using the health component of the Consumer Price Index [33]

b The cost for bone surgery was not included as the incidence was 0% for both arms in the CARD trial [25]

c Costs reported by Bui et al. [29] assumed hospitalization (aligned with clinician input)

d Cost based on CPT 99214 (outpatient visit, $110.43 (€94.9) [42] and Red Book [43] cost for pregabalin ($11.19 (€10) [42] Pregabalin dosage: 300 mg/day for 3 days + 600 mg/day for 27 days

* Assumed 92.5% outpatient management and 7.5% hospitalization with 3 days of LOS (based on clinician input)
Common Terminology Criteria for Adverse Events (CTCAE) (National Cancer Institute, 2009), including laboratory abnormalities that occurred in ≥3% of patients, in either treatment arm, in the CARD trial. Based on clinician input, events for which there is no routine treatment (i.e., an increase in aspartate transaminase or alanine transaminase) were excluded. The incidence of AEs included in the analysis is summarized in Supplementary Appendix 4. To estimate the total number of AEs, the incidence of events was multiplied by the hypothetical cohort size (n = 100). The proportions of patients with SSEs or Grade 3/4 AEs or in end-of-life care who are expected to be hospitalized or placed in the ICU, as well as the number of days in the hospital or ICU care who are expected to be hospitalized or placed in the ICU, as well as the number of days in the hospital or ICU were based on clinician input (Supplementary Appendix 5). The distribution of type of SSE was applied to estimate the total number of SSEs at 6, 12, 18, and 24 months (Supplementary Appendix 6). The number of hospitalization days for end-of-life care was obtained from Wilson et al. (2014) [27]. The rates of hospitalization and ICU admission and the LOS for each event were assumed to be the same for both cabazitaxel and a second ARTA. We excluded events for which hospital/ICU admission was not routinely expected (e.g., radiation to bone, musculoskeletal pain/discomfort, peripheral neuropathy, etc.).

Healthcare resource use costs
United States-specific estimates of HCRU costs were used in this model and were obtained from published literature [27–32]. Costs were analyzed in 2020 US dollars; in the instances where the costs were available only from previous years, the costs were inflated using the health component of the Consumer Price Index [33]. Table 1 presents the costs of SSE management and costs of Grade 3/4 AE management with their sources used in this analysis. The cumulative costs for AEs at the four time points of interest (i.e., 6, 12, 18, and 24 months) were based on the cumulative proportion of treatment administered by each time point during the CARD trial. A summary of the cumulative proportion of treatment administered and AE-related costs at each time point is provided in Supplementary Appendix 7.

Based on clinician input, it was assumed that 10% of total deaths would happen following hospitalization. The cost of end-of-life care for patients who died during hospitalization was estimated to be $130,660 (€111,061) based on Wilson et al. (2014) [27]. This cost included the average cost of the last hospitalization for severe side effects (neutropenia and cardiac events) for an average stay of 22 days. The cost per hospitalization day (assuming the inclusion of ICU costs) due to Grade 3/4 AEs and SSEs was calculated for each event as follows:

- For Grade 3/4 AEs with a 100% rate of hospitalization (i.e., diarrhea, infection, renal disorder, cardiac disorder, and febrile neutropenia), the cost per event was divided by the number of expected days of hospitalization per event.
- For AEs with less than 100% rate of hospitalization (i.e., anemia, thrombocytopenia, and hyponatremia), the cost per day was obtained from Bilir et al. (2016) [28], which provided data on both mean inpatient cost and mean LOS for these events.
- For pathological fracture and spinal cord compression, published costs for these events were divided by the expected days of hospitalization (assuming that the costs were reflective of hospitalization costs).

Finally, to calculate the total cost of hospitalization, the estimated cost per day for each event (Table 2) were multiplied by the respective number of hospitalization days for each event, and the costs of overall events were summed for 6, 12, 18, and 24 months.

### Results

#### Reference case analysis at 18 months

**Number of patients achieving rPFS, PFS, and OS at 18 months**

For a cohort of 100 patients with mCRPC, the use of cabazitaxel as a 3L treatment was estimated to result in 9 more patients achieving rPFS, 2 more patients achieving PFS, and 17 more survivors at 18 months compared with

| Event                       | US cost per hospitalization day |
|-----------------------------|---------------------------------|
| Diarrhea                    | $4134 (€3514)<sup>a</sup>      |
| Infection                   | $2422 (€2059)<sup>a</sup>      |
| Renal disorder              | $2928 (€2489)<sup>a</sup>      |
| Cardiac disorder            | $3282 (€2790)<sup>a</sup>      |
| Febrile neutropenia         | $4685 (€3982)<sup>a</sup>      |
| Anemia                      | $6111 (€5194)<sup>b</sup>      |
| Thrombocytopenia            | $5099 (€4334)<sup>b</sup>      |
| Hyponatremia                | $5232 (€4447)<sup>b</sup>      |
| Pathological fracture       | $6277 (€5335)<sup>a</sup>      |
| Spinal cord compression     | $9276 (€7885)<sup>a</sup>      |
| End of life                 | $5939 (€5048)<sup>c</sup>      |

**Abbreviations:** ICU intensive care unit, US United States

ICU costs were assumed to be part of the hospitalization costs

<sup>a</sup> To obtain the respective cost, hospitalization costs per event were divided by the length of stay or expected days of hospitalization (based on clinician input) (Supplementary Appendix 5)

<sup>b</sup> Adapted from Bilir et al. (2016) [28]

<sup>c</sup> Adapted from Wilson et al. (2014) [27]
Table 3  Number of patients in rPFS, PFS, and OS at 6, 12, and 24 months

| Outcome                                   | 6 months | 12 months | 24 months |
|-------------------------------------------|----------|-----------|-----------|
|                                            | Cabazitaxel | Second ARTA | Difference | Cabazitaxel | Second ARTA | Difference | Cabazitaxel | Second ARTA | Difference |
| rPFS (number of patients)                 | 58       | 36        | 22        | 27       | 9         | 18        | 6          | 4         | 2         |
| PFS, (number of patients)                | 36       | 16        | 21        | 10       | 3         | 7         | 0          | 0         | 0         |
| OS, (number of patients)                 | 86       | 81        | 5         | 56       | 45        | 12        | 25         | 9         | 16        |
| Hospitalization days                     | 112      | 138       | −26       | 206      | 250       | −44       | 297        | 351       | −54       |
| ICU days                                  | 5        | 7         | −2        | 6        | 8         | −2        | 7          | 8         | −1        |

Abbreviations: ARTA androgen receptor-targeted agent, ICU intensive care unit, OS overall survival, PFS progression-free survival, rPFS radiographic progression-free survival

Values correspond to a cohort of 100 patients for each treatment

* No results available for 24 months as the number at risk for PFS was 0 for both arms in the CARD trial

Table 4  Healthcare resource utilization costs at 6, 12, and 24 months

| Outcome | 6 months | 12 months | 24 months |
|---------|----------|-----------|-----------|
| SSEs    | $219,191 | $309,285  | −$90,094  | $235,745  | $321,274  | −$85,529  | $257,906  | $344,274  | −$86,368  |
| AEs     | $226,750 | $302,843  | −$76,093  | $238,962  | $325,145  | −$86,183  | $255,023  | $341,208  | −$86,185  |
| End-of-life care | $181,617 | $248,254  | −$66,637  | $201,546  | $269,822  | −$68,276  | $223,770  | $292,098  | −$68,328  |
| Total   | $627,559 | $760,382  | −$132,823 | $708,233  | $880,265  | −$172,032 | $733,236  | $923,288  | −$190,052 |

Abbreviations: AE adverse event, ARTA androgen receptor-targeted agent, SSE symptomatic skeletal event

Values correspond to a cohort of 100 patients for each treatment

a similar cohort of patients receiving a second ARTA (Fig. 1).

**Hospitalization and intensive care unit days at 18 months**

At 18 months, the use of cabazitaxel as a 3 L treatment in patients with mCRPC was estimated to result in 58 fewer hospitalization days (Fig. 2A) and 2 fewer ICU days (Fig. 2B) than in a similar cohort of patients receiving a second ARTA.

**Healthcare resource utilization and hospitalization costs**

In patients with mCRPC, the use of cabazitaxel as a 3 L treatment was estimated to avoid $323,095 (€274,630) in additional HCRU costs at 18 months compared with patients receiving a second ARTA. These HCRU cost savings were due to decreased costs of SSE management and end-of-life care (Fig. 3).

Hospitalization costs were estimated to constitute approximately 90% of the total HCRU costs for both cabazitaxel and a second ARTA (Fig. 4). At 18 months, hospitalization cost for cabazitaxel as a 3 L treatment was estimated as $1,442,870 (€1,226,440), whereas for a second ARTA, it was $1,728,394 (€1,469,135). Thus, cabazitaxel as a 3 L treatment was associated with a savings of $285,524 (€242,695) in hospitalization-related costs, compared with a second ARTA (Fig. 4). See Supplementary Appendix 8 for a summary of hospitalization-related costs.

**Scenario analyses at 6, 12, and 24 months**

Clinical and cost results at 6, 12, and 24 months were consistent with the reference case results at 18 months (Tables 3 and 4).

**Discussion**

The present cost–consequence analysis quantified the clinical and economic outcomes of using cabazitaxel versus a second ARTA as a 3 L treatment in patients with mCRPC previously treated with docetaxel and who progressed within 12 months while receiving an ARTA, from
the US payers’ perspective. This study demonstrated that, at all assessed time points, cabazitaxel was associated with improved clinical outcomes (i.e., more patients achieving rPFS, PFS, and OS) and decreased HCRU costs associated with SSEs management and end-of-life care compared with that in a same-size cohort receiving a second ARTA.

Prostate cancer is associated with high HCRU [21]. Given that the occurrence of SSEs contributes significantly to the economic burden of patients with mCRPC, the reduction in costs associated with SSEs management is of particular interest [34]. Costs for the management of SSEs have been reported to constitute approximately 30% of the total claims for Medicare-enrolled men with prostate cancer in the US between the date experiencing the first SSE and the date of death [22]. In the CARD trial, cabazitaxel was associated with a 36% reduction in the risk of death due to any cause [19] and lower rates of SSEs despite the lower use of bone-targeted agent at baseline [25]. Importantly, our analysis estimated a 21% reduction in costs associated with SSEs management with the use of cabazitaxel as a 3L treatment compared with a second ARTA at 18 months, primarily due to reduced

![Graph of rPFS, PFS, and OS at 18 months. ARTA, androgen receptor-targeted agent; OS, overall survival; PFS, progression-free survival; rPFS, radiographic progression-free survival. The number correspond to a cohort of 100 patients for each treatment](image1)

![Graph of hospitalization days and ICU days at 18 months. ARTA, androgen receptor-targeted agent; ICU, intensive care unit. The number correspond to a cohort of 100 patients for each treatment](image2)
hospitalization costs. In addition to the economic benefits, prevention or delay in SSEs improves the quality of life of patients with mCRPC [35–37].

In the present analysis, the estimate of AE-related costs was 10% higher for cabazitaxel at 18 months; however, this difference was offset by the cost savings related to SSE management and end-of-life care. Hospitalization costs were estimated to constitute approximately 90% (range: 87–91%) of the total costs for both cabazitaxel and a second ARTA at all assessed time points. Cabazitaxel was associated with a 17% decrease in hospitalization-related costs at 18 months. Overall, this cost–consequence analysis suggested that cabazitaxel as a 3L treatment for patients with mCRPC, compared with a same-size cohort receiving a second ARTA, results in net savings with improvement in the time to disease progression. These results are in line with a previous budget impact analysis where a hypothetical increase (from 24 to 33%) in the use of cabazitaxel as a second-line treatment was estimated to result in cost savings of $86,136 (USD 2015) in patients with mCRPC previously treated with docetaxel compared with ARTAs [38].
Although a standard clinical treatment pattern has not been established for patients with mCRPC, under real-world conditions, abiraterone is increasingly being used as a second-line treatment owing to lower drug acquisition costs [39]. However, certain patients with mCRPC progress during treatment with an ARTA [40]. Thus, upon progression on an ARTA before or after docetaxel, clinicians can use either cabazitaxel or an alternative ARTA as a 3L treatment. The available evidence from the CARD trial supports the use of cabazitaxel over a second ARTA in terms of both clinical outcomes (rPFS, PFS, and OS) and quality of life (pain response, pain progression, and SSEs) [19, 25]. The current analysis suggests that the use of cabazitaxel as a 3L treatment for patients with mCRPC results in HCRU cost savings versus a second ARTA. Considering this evidence, cabazitaxel offers advantages in terms of improved clinical outcomes and lower healthcare costs versus a second ARTA (abiraterone or enzalutamide) for managing patients with mCRPC who were previously treated with docetaxel and had progressed while receiving an ARTA. Future research should include assessment of economic outcomes in parallel with clinical outcomes in primary comparative studies of various treatment options.

There are limitations associated with this analysis. These results reflect the outcomes expected for a patient population reflective of the CARD trial population; therefore, their generalizability to populations often not well represented in clinical trials, such as racial minorities and patients with poor performance or comorbidities, may be limited. Additionally, applicability of this data to other mCRPC patients (e.g., 2L after 1L ARTA [no prior chemotherapy], or prior treatment on ARTA more than 12 months) is also limited. The CARD trial evaluated the 25 mg/m² dose of cabazitaxel, while 20 mg/m² is routinely used in clinical practice in the US. However, no major difference in efficacy is expected between the two doses based on the PROSELICA study [41] and input from clinicians. Moreover, modelling the safety profile based on the 25 mg/m² dose was considered a conservative approach for the analysis as this would bias the analysis to higher rates of complications and costs of treatment if bias was introduced. In real-world practice, patients treated with cabazitaxel are those who are generally assessed to have a better performance status and life expectancy than those who undergo a second ARTA, which may contribute to bias in the study results. This analysis is from the US payers’ and population healthcare decision makers’ perspective; therefore, indirect costs (e.g., caregiver burden, lost productivity, etc.) were not considered. Additionally, we considered only those Grade 3/4 AEs for which there is a need for hospitalization, which substantively affects the quality of life. The inclusion of Grades 1 and 2 AEs may minimally impact model projections. Lastly, for informing some model inputs (i.e., rates of hospitalization and LOS for most of the AEs and SSEs), oncology practicing clinicians’ feedback was utilized due to a lack of published literature.

**Conclusion**

The use of cabazitaxel as a 3L treatment after docetaxel and an ARTA in patients with mCRPC is estimated to result in clinical benefits (i.e., longer rPFS, PFS, and OS) and lower healthcare resource utilization (fewer hospitalization and ICU days), compared with a second ARTA.

**Abbreviations**

AEs: Adverse events; ARTA: Androgen receptor-targeted agent; ASTI: Androgen-signaling-targeted inhibitor; CPT: Current Procedural Terminology; CRPC: Castration-resistant prostate cancer; HCRU: Healthcare resource utilization; CTCAE: Common Terminology Criteria for Adverse Events; ICU: Intensive care unit; KM: Kaplan–Meier; LOS: Length of stay; mCRPC: Metastatic castration-resistant prostate cancer; NCI: National Cancer Institute; OS: Overall survival; PFS: Progression-free survival; rPFS: Radiographic progression-free survival; SSE: Symptomatic skeletal event; 3L: Third-line; US: United States; USD: US dollar.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12913-022-08274-x.

**Additional file 1.**

**Acknowledgments**

The authors would like to acknowledge Riccardo Sibilano, Ph.D.; Medha Sasane, Ph.D. and Remi Castan, Ph.D. for their critical review of the manuscript. The medical writing support was provided by Amit Kandhare, Ph.D. and Amit Garg, MS from Sanofi.

**Prior presentation**

In less detail, these data were presented as poster at the ESMO Virtual Congress 2021, 16th-21st Sep 2021 (Poster 587P); ESMO Abstract # 1154. Annals of Oncology. 2021,32(Suppl_5):S626-S677. Congress URL: https://www.esmo.org/meetings/esmo-congress-2021.

**Authors’ contributions**

AKM, TH, AKG, DG, AZ, ED and NJV were involved in the design of the study, data analysis and interpretation. DG, AZ, ED and AKM developed the initial draft of the manuscript; TH, AKG and NJV supported critical review and development of the final drafts. All the authors critically reviewed and approved the final manuscript draft for publication.

**Funding**

Sanofi provided financial support for the conduct of the study and medical writing assistance.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.
Consent for publication
Not applicable.

Competing interests
AKG reported receiving: honoraria and advisory fees from Genentech, AstraZeneca, Sanofi, Bayer, Astellas Pharma, Janssen, Advanced Accelerator Applications, Myovant Sciences, and Exelisix; advisory fees from Blue Earth Diagnostics; honoraria from Astellas Scientific and Medical Affairs Inc., Janssen Oncology, Clovis Oncology, and Pfizer; grant support from Astellas Scientific and Medical Affairs Inc., Bayer, Seattle Genetics/Astellas, Genentech, and AstraZeneca; and travel support from Sanofi. TH reports receiving honoraria, advisory fees, grant support, and fees for serving on a speaker’s bureau from Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Eisai, and Exelisix; honoraria, advisory fees, and fees for serving on a speakers bureau from Astellas Pharma; and honoraria and advisory fees from Novartis and Bayer/Onyx. AKG reported being employed by EVERSANA and holding stock in Tyme Technologies and Area Biopharma. DG and AZ reported being employed by EVERSANA. ED reported being employed by and holding stock in Sanofi. NJV reported being employed by and receiving travel and grant support from US Oncology, advisory fees, travel support, and fees for serving on a speakers bureau from Bayer, Genentech/Roche, and AstraZeneca; advisory fees and fees for serving on a speakers bureau from Clovis Oncology and Myovant Sciences; advisory fees, travel support, and honoraria from Pfizer; honoraria and fees for serving as an expert testimony from Novartis, advisory fees, grant support, and honoraria from Merck; travel support and fees for serving on a speakers bureau from Sanofi, advisory fees and holding stock in Cars Life Sciences; advisory fees from Tolero Pharmaceuticals, Astellas Pharma, Boehringer Ingelheim, Corvus Pharmaceuticals, Medra Pharmaceuticals, Janssen Oncology, and Eisai; fees for serving on a speakers bureau from Bristol-Myers Squibb, Seattle Genetics/Astellas, and AVEO; travel support from Exelixis; honoraria from UpToDateand; grant support from Endocyte and Szuho Kintor Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.

Author details
1 Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
2 US Oncology, Texas Oncology, Dallas, TX, USA.
3 CRG-EVERSANA Canada Inc., 3228 South Service Road, Suite 204, Burlington, ON L7N 3H8, Canada.
4 Sanofi, Cambridge, MA, USA.
5 US Oncology Research, Las Vegas, NV, USA.

Received: 11 October 2021 Accepted: 27 June 2022
Published online: 14 July 2022

References
1. American Cancer Society: Cancer facts & figures 2020. Estimated number of new cancer cases and deaths by sex, US, 2020 [https://www.cancer.org/content/dam/cancer.org/research/cancer-facts-and-statistics/annual cancer-facts-and-figures/2020/estimated-number-of-new-cancer-cases-and-deaths-by-sex-2020.pdf].
2. Tamada S, Iuchi T, Kato M, Asakawa J, Kita K, Yasuda S, et al. Time to progression to castration-resistant prostate cancer after combining androgen blockade for advanced hormone-sensitive prostate cancer. Oncotarget. 2018;9(97):36966–74. https://doi.org/10.18632/oncotarget.26426.
3. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54. https://doi.org/10.1016/S0140-6736(10)60053-4.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. https://doi.org/10.1056/NEJMoa0402720.
5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Pensom DF, et al. Spireucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. https://doi.org/10.1056/NEJMoa1000194.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(3):1187–97. https://doi.org/10.1056/NEJMoa1207506.
7. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. https://doi.org/10.1056/NEJMoa1104618.
8. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. https://doi.org/10.1056/NEJMoa1213755.
9. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbari K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(2):1091–103. https://doi.org/10.1056/NEJMoa2073512.
10. Zheng H, Chen J, QuW, Lin S, Chen Y, Liang G, et al. Safety and efficacy of first-line treatments for chemotherapy-naive metastatic castration-resistant prostate Cancer: a systematic review and indirect comparison. Biomed Res Int. 2017;2017:3941217. https://doi.org/10.1155/2017/3941217.
11. Tran K, McCormack S. CADDTH rapid response reports. In: Androgen receptor targeted agents for castration resistant prostate Cancer: a review of clinical effectiveness and cost-effectiveness. Edn. Ottawa: Canadian Agency for Drugs and Technologies in Health. Copyright © 2019 Canadian Agency for Drugs and Technologies in Health; 2019.
12. Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer. 2014;120(7):968–75. https://doi.org/10.1002/cncr.28518.
13. Blanchini D, Lorente D, Rodriguez-Vida A, Olmin A, Pezaro C, Ferralideschi R, et al. Antimutivity activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer. 2014;50(1):78–84. https://doi.org/10.1016/j.ejca.2013.08.020.
14. Loriot Y, Blanchini D, Ileana E, Sandhu S, Patrignoulo A, Pezaro C, et al. Antimutivity activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24(7):1807–12. https://doi.org/10.1093/annonc/mdt136.
15. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802–7. https://doi.org/10.1093/annonc/mdt138.
16. Schradner AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajil T, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol. 2014;65(1):130–6. https://doi.org/10.1016/j.eururo.2013.06.042.
17. Thomsen FB, Roder MA, Rathenborg P, Brasso K, Borre M, Iversen P. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol. 2014;48(3):268–75. https://doi.org/10.1080/21681805.2013.860189.
18. van Soest RJ, Nieuweboer AJ, de Morree ES, Chitu D, Bergman AM, Goey SH, et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2015;51(17):2562–9. https://doi.org/10.1016/ j.ejca.2015.07.037.
19. de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulffing C, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019;381(26):2506–18. https://doi.org/10.1056/NEJMoa1911206.
20. Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, et al. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials. Eur J Cancer. 2016;61:111–21. https://doi.org/10.1016/j.ejca.2016.04.002.
21. Satoh T, Ledesma D, Yoshihara N. The economic burden of metastatic castration resistant prostate Cancer and skeletal related events in Japanese University hospitals. Asian Pac J Cancer Prev. 2018;19(1):21–6. https://doi.org/10.22034/APJCP.2018.19.1.21.
22. McDougall IA, Bansal A, Garrit BH, McCune JS, Karnopp A, Fedorenko C, et al. The clinical and economic impacts of skeletal-related events among Medicare enrollees with prostate Cancer metastatic to bone. Oncologist. 2016;21(3):320–6. https://doi.org/10.1634/theoncologist.2015-0327.
23. Grochtdreis T, Konig HH, Dobruschkin A, von Amsberg G, Dams J. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: a systematic review. PLoS One. 2018;13(12):e0208063. https://doi.org/10.1371/journal.pone.0208063

24. Siddiqui M, Bajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87(10):935–43. https://doi.org/10.1016/j.mayocp.2012.07.007

25. Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, et al. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncol. 2020;21(11):1513–25. https://doi.org/10.1016/S1470-2045(20)30449-6

26. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2007;25(1):3–6. https://doi.org/10.2165/00019053-20072501-00002

27. Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, et al. New therapeutic options in metastatic castration-resistant prostate cancer: can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Pract. 2014;20(8):417–25. https://doi.org/10.1177/1078155313509505

28. Bilir SP, Ma Q, Zhao Z, Wéhler E, Munakata J, Barber B. Economic burden of toxicities associated with treating metastatic melanoma in the United States. Am Health Drug Benefits. 2016;9(4):203–13

29. Bui CN, D’Kay L, Flanders S, Ostreicher N, Francis P, Posta L, et al. Budget impact of Enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2016;22(2):163–70. https://doi.org/10.18855/jmcp.2016.22.2.163

30. Carter JA, Xi X, Botteman MF. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):483–96. https://doi.org/10.1586/14737167.2013.820959

31. Roy A, Kish JK, Bloudek L, Siegel DS, Jagannath S, Globe D, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204–15

32. Sorensen S, Ellis L, Wu Y, Hutchins V, Linnehan JE, Senbetta M. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Manag Care Pharm. 2013;19(9):799–808. https://doi.org/10.18553/jmcp.2013.19.9.799

33. CRG-EVERSANA Canada Inc. Data on file. Cost inflation tool. 2020

34. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15(7):869–76. https://doi.org/10.1007/s00520-006-0203-x

35. Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O’Sullivan JM, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27(5):868–74. https://doi.org/10.1093/annonc/mdw020

36. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2007;25(1):3–6. https://doi.org/10.2165/00019053-20072501-00002

37. Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, et al. New therapeutic options in metastatic castration-resistant prostate cancer: can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Pract. 2014;20(8):417–25. https://doi.org/10.1177/1078155313509505

38. Bilir SP, Ma Q, Zhao Z, Wéhler E, Munakata J, Barber B. Economic burden of toxicities associated with treating metastatic melanoma in the United States. Am Health Drug Benefits. 2016;9(4):203–13

39. Bui CN, D’Kay L, Flanders S, Ostreicher N, Francis P, Posta L, et al. Budget impact of Enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2016;22(2):163–70. https://doi.org/10.18855/jmcp.2016.22.2.163

40. Carter JA, Xi X, Botteman MF. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):483–96. https://doi.org/10.1586/14737167.2013.820959

41. Roy A, Kish JK, Bloudek L, Siegel DS, Jagannath S, Globe D, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204–15

42. Sorensen S, Ellis L, Wu Y, Hutchins V, Linnehan JE, Senbetta M. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Manag Care Pharm. 2013;19(9):799–808. https://doi.org/10.18553/jmcp.2013.19.9.799

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.